Zhitong Financial App News, Deqi Pharmaceutical-B (06996.HK) issued an announcement to conclude an exclusive global licensing agreement between the company (as licensor) and UCB (as licensee) for the CD19/CD3 bispecific T-cell connector (TCE) antibody ATG-201. The Group has received an initial down payment of US$60 million from UCB. The receipt of the down payment under this landmark agreement with UCB (UCB) further consolidated the Group's cash position and provided strong financial support to advance the development of the Group's innovative drug pipeline and accelerate the benefits of more patients.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.